Exploring Alternative Pain Management Strategies for Headaches and Migraines | AMCP Nexus 2024
New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.
Migraine, a debilitating neurological condition, places a significant burden on individuals and health care systems. Patients often seek various treatment options to manage their symptoms effectively. A collection of posters at the AMCP Nexus 2024 Annual Meeting, held in Las Vegas from October 14 to 17, examined the effectiveness and cost-effectiveness of pain management strategies for the condition.
READ MORE: Nonopioid Pain Management Resource Center
Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.
References
1. Ailani J, Blumenfeld A, Ahmadyar G, et al. Long-term persistence of patients with chronic migraine switching to onabotulinumtoxinA or a different calcitonin gene-related peptide monoclonal antibody (CGRP mAb) after initial CGRP mAb treatment. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV. Poster G40.
2. Blumenfeld A, Ailani J, Ahmadyar G, et al. Long-term persistence of onabotulinumtoxinA vs calcitonin gene-related peptide monoclonal antibodies in new initiators with chronic migraine. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV. Poster G41.
3. Yang A, Xie H, Zhang Y, Chatterjee S, Ortega M, Driessen M. Comparative analysis of fremanezumab vs preventive gepants for the prevention of episodic migraine on migraine-related health care resource utilization and direct costs. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV. Poster G42.
4. Gokhale P, Villa-Zapata L. Cost-effectiveness analysis of Ubrogepant, Rimegepant, and zavegepant compared with each other and usual care for the acute treatment of migraine. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV. Poster G43.
5. Atkinson C, Wallis H, Amet M, Quinones E, Park T, Shah D, et al. Benefits of an educational migraine program on those living with migraine in the workplace: The ENLIGHTEN study. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV. Poster G38.
Q&A: Factors Showing Tirzepatide is More Beneficial Than Semaglutide | ASHP Midyear
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.
